NASDAQ:ORGO
Organogenesis Holdings Inc.
Organogenesis Holdings Inc.'s revenue grew 17.0% in fiscal 2025 to $564.2M while operating margin rose to 7.9%. Free cash flow was −$24.5M, −4.3% of revenue, and the diluted share count fell 1.1%.Summary generated from Organogenesis Holdings Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$564.2M
Revenue growth+17.0%
Revenue, 5-yr CAGR+10.8%
Gross marginn/a
Operating margin7.9%
Net margin6.6%
ROICn/a
Return on equity13.2%
Debt / equityn/a
Free cash flow−$24.5M
FCF margin−4.3%
Share count change−1.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 467 | 451 | 433 | 482 | 564 |
| Operating income | 72 | 22 | 13 | −1 | 45 |
| Net income | 94 | 16 | 5 | 1 | 37 |
| Free cash flow | 31 | −9 | 7 | 4 | −24 |
Recent filings
- 8-KEntry into a material agreement
Aug 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 6, 2026 - 8-KResults of operations and financial condition
Aug 6, 2026 - 8-KDirector or officer change
Jun 16, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026 - 8-KResults of operations and financial condition
May 7, 2026 - DEF 14AProxy statement
Apr 30, 2026 - 4Insider transaction report
Apr 24, 2026